Two medication classes found to reduce cardiovascular and liver events in people with type 2 diabetes
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ...
Jun 3, 2024
0
0